Effectiveness of an Infliximab Biosimilar vs. Originator in Inflammatory Bowel Diseases
This study demonstrated noninferiority of infliximab biosimilar CT-P13 in comparison to the original in long-term management of IBD.
Authors
- Amir Ben‐Tov (ORCID: https://orcid.org/0000-0001-9627-7626)
- Iris Dotan (ORCID: https://orcid.org/0000-0002-8005-7706)
- Galia Zacay (ORCID: https://orcid.org/0000-0002-0722-7326)
- Oren Ledder (ORCID: https://orcid.org/0000-0001-8109-814X)
- Yiska Loewenberg Weisband (ORCID: https://orcid.org/0000-0002-5064-5902)
- Dan Turner (ORCID: https://orcid.org/0000-0001-5160-868X)
- Hadas Labrisch-Kaye
- Rachel Buchuk (ORCID: https://orcid.org/0000-0001-5059-2364)
- Earl N. Metz
Institutions
- Hebrew University of Jerusalem (IL)
- Rabin Medical Center (IL)
- Shaare Zedek Medical Center (IL)
- Clalit Health Services (IL)
Publication Details
- Journal
- Journal of Clinical Gastroenterology
- Published
- 2025-10-16
- DOI
- https://doi.org/10.1097/mcg.0000000000002263
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00